Results 11 to 20 of about 25,581,606 (307)

Gut microbiota alterations in patients with non-small-cell lung cancer undergoing chemoradiotherapy. [PDF]

open access: yesMol Oncol
We investigated the impact of concurrent chemoradiotherapy (CRT) on the gut microbiota in patients with locally advanced non‐small‐cell lung cancer. Overall gut microbiota composition remained largely stable throughout CRT while antibiotic exposure may influence microbial diversity.
Nymoen HM   +19 more
europepmc   +2 more sources

Targeting DNA methyltransferases in non-small-cell lung cancer [PDF]

open access: yes, 2021
Despite the advances in treatment using chemotherapy or targeted therapies, due to static survival rates, non-small cell lung cancer (NSCLC) is the major cause of cancer-related deaths worldwide.
Wilson, C.   +3 more
core   +1 more source

Expert Consensus on Prevention and Treatment of COVID-19 Infection in Patients with Lung Cancer

open access: yesChinese Journal of Lung Cancer, 2023
Corona virus disease 2019 (COVID-19) infection has become a major public health issue affecting human health. The main goal of epidemic prevention and control at the current stage in China is to “protect people’s health and prevent severe cases ...
Non-small Cell Lung Cancer Expert Committee of Chinese Society of Clinical Oncology   +1 more
doaj   +1 more source

Advanced non-small-cell lung cancer: how to manage non-oncogene disease Andrea De Giglio, Alessandro Di Federico, Chiara De

open access: yesDrugs in Context, 2022
The therapeutic approach to patients affected by advanced non-small-cell lung cancer (NSCLC) is facing rapid and continuous evolution. In recent years, the emergence of new treatment strategies, such as immunotherapy and tyrosine kinase inhibitors, has ...
Andrea De Giglio   +5 more
doaj   +1 more source

The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks [PDF]

open access: yes, 2023
: This Editorial by De Giglio, Ricciuti and Metro introduces the series Treatment of advanced non-small-cell lung cancer: one size does not fit all: https://www.drugsincontext.com/special_issues/treatment-of-advanced-non-small-cell-lung-cancer-one-size ...
Ricciuti B.   +8 more
core   +1 more source

Erlotinib in patients with previously irradiated, recurrent brain metastases from non-small cell lung cancer: Two case reports [PDF]

open access: yes, 2008
Background: With the current improvements in primary lung care, the long-term control of brain metastases becomes a clinical challenge. No established therapeutic approaches exist for cranial relapse after response to previous radiotherapy and systemic ...
Pawel, Joachim   +3 more
core   +1 more source

Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer

open access: yesChinese Journal of Lung Cancer, 2021
Lung cancer is one of the malignant tumors with the highest morbidity and mortality in the world. Immune checkpoint inhibitors (ICIs), including programmed cell death 1 (PD-1) antibody, programmed cell death ligand 1 (PD-L1) antibody, and cytotoxic T ...
Chinese Society of Clinical Oncology, Expert Committee on Tumor Vascular-targeted Therapy   +1 more
doaj   +1 more source

Preoperative CYFRA 21-1 and CEA as Prognostic Factors in Patients with Stage I Non-Small Cell Lung Cancer [PDF]

open access: yes, 2008
Objective: To validate the prognostic value of preoperative levels of CYFRA 21-1, CEA and the corresponding tumor marker index (TMI) in patients with stage I non-small cell lung cancer (NSCLC). Methods: Two hundred forty stage I NSCLC patients (80 in pT1
Hatz, Rudolf   +8 more
core   +1 more source

MicroRNA-24 in Cancer: A Double Side Medal With Opposite Properties

open access: yesFrontiers in Oncology, 2020
MicroRNA-24 (miR-24) has been widely studied in a variety of human cancers, which plays different roles in specific type of cancers. In the present review, we summarized the recent surveys regarding the role of miR-24 in different human cancers.
Sumei Wang   +18 more
doaj   +1 more source

Non-small-cell lung cancer: how to manage RET-positive disease

open access: yesDrugs in Context, 2022
Targeted therapy has dramatically changed the history and outcomes of oncogene-addicted non-small-cell lung cancer (NSCLC). RET rearrangements are typically observed in about 1–2% of NSCLC, resulting in constitutive activation of downstream signalling ...
Elisa Andrini   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy